teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 40 Projects Releases Packages Wiki Activity Actions 1

auto-fix: strip 2 broken wiki links
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-20 04:57:32 +00:00
parent aa6751e029
commit c404742dae
2 changed files with 2 additions and 2 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -121,7 +121,7 @@ If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg rega
### Additional Evidence (challenge)
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19*
Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself.

2
domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
View file

@ -45,7 +45,7 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for
### Additional Evidence (confirm)
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-18*
Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding.